If you are reading this post then you probably already know that metastatic melanoma is an aggressive cancer with a 10 year survival rate of less than 10%. Further, the standard FDA approved chemotherapy for Melanoma called Dacarbazine when used as a single agent has a response rate of between 5%-20%.
The study linked and excerpted below does say that high-dose interleukin “benefits a small subset of patients” but do you want to place your hopes on a being in a “small subset of patients?”
There are dozens of evidence-based non-toxic therapies that 1) are cytotoxic to melanoma and/or 2) work synergistically with dacarbazine to enhance it’s efficacy. The reason why your oncologist doesn’t talk about these therapies is because they are not approved by the Food and Drug Administration. Drug companies don’t spend millions of dollars to test non-conventional therapies that can’t be patented.
Click the illustration below to enlarge this mind map.
The important takeaway from this blog post is that there are evidence-based therapies beyond conventional methods to help you fight your melanoma.
I am both a long-term survivor of an incurable cancer and a cancer coach. Years of experience and research have taught me that cancer patients owe it to themselves to pursue evidence-based therapies beyond what conventional oncology offers.
To learn more about therapies to enhance the efficacy of conventional melanoma chemotherapy scroll down the page to post a question or a comment. I will reply to you ASAP.
“The 10-year survival rate for patients with metastatic melanoma is less than 10%. Although surgery and radiation therapy have a role in the treatment of metastatic disease, systemic therapy is the mainstay of treatment for most patients. Single-agent chemotherapy is well tolerated but is associated with response rates of only 5% to 20%…
High-dose interleukin-2 (HD IL-2 [Proleukin]), approved by the FDA in 1998 for metastatic melanoma, benefits a small subset of patients…
Three groups of patients were identified: those with cutaneous, nodal, or gastrointestinal tract metastases; those with isolated pulmonary metastases; and those with liver, brain, or bone metastases. The median survivals in these three groups were 12.5, 8.3, and 4.4 months, respectively. The 5-year actuarial survivals were 14%, 4%, and 3%, respectively. In addition to the site of disease, the presence of an elevated serum lactate dehydrogenase (LDH) has also been associated with poor prognosis.[4,5]…”